Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-BAFFR monoclonal antibody ESG206

A monoclonal antibody that is directed against the tumor-associated antigen (TAA) B-cell activating factor receptor (BAFFR; tumor necrosis factor receptor superfamily member 13C; TNFRSF13C; BLyS receptor 3; BR3), with potential antineoplastic activity. Upon administration, anti-BAFFR monoclonal antibody ESG206 binds to and blocks BAFFR. This prevents BAFFR-mediated signaling and may kill BAFFR-expressing tumor cells. BAFFR, a protein belonging to the TNF receptor superfamily, is expressed on the surface of certain types of cancer cells, including B-cell acute lymphoblastic leukemia. It plays a key role in the regulation of peripheral B-cell survival.
Code name:ESG 206
ESG-206
ESG206
Search NCI's Drug Dictionary